Form 8-K - Current report:
SEC Accession No. 0001213900-22-021801
Filing Date
2022-04-27
Accepted
2022-04-27 09:00:40
Documents
14
Period of Report
2022-04-27
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea158566-8k_abvcbio.htm   iXBRL 8-K 28407
2 NOTICE TO SHAREHOLDERS ea158566ex99-1_abvcbio.htm EX-99.1 365061
3 FORM OF PROXY CARD ea158566ex99-2_abvcbio.htm EX-99.2 28020
  Complete submission text file 0001213900-22-021801.txt   658918

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abvc-20220427.xsd EX-101.SCH 3039
5 XBRL LABEL FILE abvc-20220427_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE abvc-20220427_pre.xml EX-101.PRE 22599
8 EXTRACTED XBRL INSTANCE DOCUMENT ea158566-8k_abvcbio_htm.xml XML 3494
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 22856550
SIC: 2834 Pharmaceutical Preparations